SELADEPAR



NAME OF DRUG : SELADEPAR

ALSO KNOWN AS : MBX_8025

LABORATORY : CYMABAY_THERAPEUTICS

STATUS AND ADVANCEMENT

Type of drug : PPAR delta receptor agonist

Clinical trials advancement : Recruiting Phase 2b

Estimated time to market : 106 months.

LABORATORY ABSTRACT ON THE DRUG

Data from our Phase 2 clinical trial in patients with mixed dyslipidemia as well as evidence from other PPARδ agonists, suggest that seladelpar may have utility in treating patients with NASH. In this study, seladelpar treatment decreased the triglyceride content of serum lipoproteins, which because they are derived from the liver, strongly suggested that seladelpar lowers hepatic fat. Our clinical experience with seladelpar leads us to believe that it could potentially benefit patients affected with NAFLD who are further at risk of developing NASH. Recently, seladelpar was found to decrease fibrosis, inflammation, hepatic lipids and reverse insulin resistance in the foz/foz mouse which is a diabetic obese mouse model of NASH.

RECENT NEWS ON SELADEPAR

SOME PUBLICATIONS RELATED WITH SELADEPAR

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH SELADEPAR


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE